Ad Header



The Pulse of the Pharmaceutical Industry

Pluristem sees positive results from leg pain study

Written by: | | Dated: Tuesday, June 12th, 2018


Israel’s Pluristem sees positive results from leg pain study


TEL AVIV (Reuters) – Israel’s Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Pluristem said its PLX-PAD treatment reduced incidence of revascularization and improved patients’ mobility.

IC – muscle pain and weakness brought on by exercise – is usually associated with early-stage peripheral artery disease and if not treated can progress to critical limb ischemia (CLI), where patients are at risk of leg amputation and death.

The Phase II study was designed to evaluate the safety, efficacy and optimal dosing regimen for PLX-PAD cells in patients with IC. Enrollment took place at 28 clinical sites in the United States, Germany, South Korea and Israel.

The study’s results also validate the design of Pluralism’s advanced Phase III trial for CLI, the company said.


Reporting by Tova Cohen, Editing by Ari Rabinovitch


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom